Diethylcarbamazine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as the citrate salt of N,N-diethyl-4-methylpiperazine-1-carboxamide, CAS 1642-54-2, with a molecular weight of 391.42 g/mol and molecular formula C₁₀H₂₁N₃O·C₆H₈O₇. The material is a white to off-white crystalline powder intended for incorporation into the listed dosage forms. Compendial starting-material controls for Diethylcarbamazine Citrate typically specify assay on the dried basis within 98.0–102.0%, a loss on drying consistent with stable solid-dose processing, and chromatographic purity limits for related piperazine derivatives; exact residual solvent and related-substance thresholds should be aligned to the receiving dosage form and current monograph edition. Because the substance is freely soluble in water, it is susceptible to surface moisture uptake during open dispensing at relative humidity above 60%; pre-drying in a vacuum dryer or dry-room storage is therefore a standard handling boundary. Physical grades are designated by particle-size classification rather than by a single model: milled grade for capsules, micronized grade for aqueous solutions, and controlled-flow grade for direct compression.

Regulatory documentation for this veterinary-grade material is not identical to human-use API documentation. A certificate of analysis, residual solvent statement, elemental impurity risk assessment, and TSE/BSE declaration are typically required before release. The product is handled under veterinary pharmaceutical quality systems, which affects documentation of starting material traceability, residual solvent testing according to VICH GL18, and control of manufacturing impurities. The core chemical identity is the same as that used in human filariasis therapy, but the regulatory pathway, permitted residual solvent profile, and packaging controls differ by jurisdiction.

Why Does Solid-Dose Processing Require Different Particle-Size and Moisture Specifications for DEC Citrate?

In tablet manufacture, particle-size distribution interacts with binder selection and compression force. Laser diffraction per USP<429> is used because sieve analysis under-reports fine aggregates. For immediate-release tablets, the citrate salt can be blended with microcrystalline cellulose and croscarmellose sodium, but a D90 above 250 µm may produce content uniformity failures in low-dose formulations, while a D50 below 20 µm can reduce flow through a gravity-fed die table. Compression force runs should be conducted because the crystalline material exhibits plastic deformation; a high-fine fraction may increase dwell-time sensitivity. Published data for this specific configuration is limited, so process parameters should be confirmed with compaction simulator studies rather than transferred from other salts.

For capsules, bulk density per USP<616> and powder flow per USP<1174> are monitored. Static charge can cause adhesion to gelatin or hypromellose shell walls, especially at low ambient humidity below 30% RH. Magnesium stearate is used at low levels; overlubrication can reduce compactibility, so inclusion should be determined by compaction studies and is typically held below 1.0% w/w in direct-fill formulations. Dosator-type capsule machines require a consistent powder column height, while tamping-pin machines tolerate higher fines but may require anti-static processing aids. Powders for oral solution or in-bottle reconstitution require controlled surface wetting and low residual moisture because the citrate salt cakes readily; desiccant systems should be sized using moisture vapor transmission rate data.

Granulation routes vary: high-shear granulation with aqueous binder increases the risk of over-wetting due to the high aqueous solubility of the citrate salt; fluid-bed granulation can provide better granule size uniformity but requires spray-rate control. Loss on drying by USP<731> should be measured after drying; granule moisture above 2.5% may cause picking and sticking on tablet tooling. Karl Fischer titration per USP<921> is preferred over loss-on-drying where bound water is suspected. Dry granulation by roller compaction may be used for moisture-sensitive formulations, but the brittle-ductile transition of the citrate salt requires roll pressure and screen-size optimization to avoid excessive fines.

When the API Is Selected for Granules, Premix and Medicated Feed Lines

Feed premix applications require carrier adhesion and homogeneity. A 1% or 10% trituration is normally prepared before blending into final feed; the API should be layered onto a carrier such as ground limestone, corncob fraction, or soybean mill run. The critical failure mode is segregation during vibratory transfer or auger filling. Ribbon blenders with shaft speeds in the range of 20–40 rpm and mixing times of 10–15 min are common; however, additional mixing time does not compensate for charge-induced clumping. Bulk density and particle-size overlap between API and carrier should be measured to reduce segregation. Electrostatic dissipation through controlled humidity or grounded transfer lines is commonly required during dry premix production.

Homogeneity testing in medicated feed is confirmed according to regulatory expectations in FDA 21 CFR 225 and EU Regulation (EU) 2019/6; sampling points at beginning, middle, and end of the batch are used to calculate coefficient of variation, with an acceptance criterion often set at ≤5% for labeled drug content in feed. Final feed mill validation should include flushability testing and carryover determination because the API is active at low inclusion rates and residual drug carryover in shared production lines must be controlled. Cross-contamination limits should be established from the carryover data, not from visual inspection alone.

Granules for oral administration are produced by wet granulation, extrusion-spheronization, or top-spray fluid-bed granulation. For diethylcarbamazine citrate, extrusion-spheronization can generate dense pellets, but the high aqueous solubility of the salt may lead to over-granulation and fines generation if water addition exceeds 12% w/w. Process analytical technology based on near-infrared moisture readings is used to halt drying before the granule bed reaches a glassy surface state. In fluid-bed processing, inlet air dew point should be controlled above 5°C and below 12°C to prevent static buildup while avoiding excessive wetting. Published data for this specific configuration is limited, so pilot-scale drying curves should be generated before defining commercial scale limits.

Injectable Solution Sterility, Endotoxin and pH Boundaries

Injectable preparations require control of bacterial endotoxin because the route bypasses gastrointestinal barriers. The API must be sourced with a validated endotoxin limit; for a veterinary injectable solution, bacterial endotoxins are controlled by USP<85> with a product-specific limit derived from maximum dose, not as a universal API limit. Sterility of the finished injection is verified by USP<71> after terminal sterilization or aseptic filtration. Particulate matter for injectable solutions is tested per USP<788> and requires particle counts for ≥10 µm and ≥25 µm sizes. Pre-filtration bioburden should be controlled with membrane filtration, and sterilizing-grade 0.22 µm filters are used when terminal sterilization is not possible. Terminal moist-heat sterilization at 121°C for 15 min may be evaluated only after confirming thermal stability of the aqueous solution; otherwise, aseptic filtration followed by integrity testing is required.

The citrate salt is freely soluble in water; however, solution stability is pH-dependent. A 5% aqueous solution has an acidic pH, and process pH should be maintained in a narrow band to avoid precipitation and reduce hydrolytic degradation of the piperazine ring. Forced degradation studies should include acidic, alkaline, oxidative, thermal, and photolytic stress as part of the veterinary dossier. Published data for this specific degradation pathway is limited, and the exact pH-dependent rate constants should be obtained from development batches rather than assumed from the solid-state stability profile. Buffers should be selected for compatibility with the piperazine group; citrate or acetate buffers are avoided where pH drift during terminal sterilization is observed.

Stainless steel or glass-lined mixing vessels are preferred for injectable compounding. Strong oxidizing agents and acidic chlorinated cleaning agents should be avoided because they can promote degradation. Nitrogen blanketing may be required for oxygen-sensitive formulation variants; the necessity is determined by dissolved oxygen testing on pilot batches. Solution filtration train design should include a prefilter for particulates and a final sterilizing-grade membrane; compatibility of the membrane with the citrate salt and any co-solvents should be confirmed before scale-up.

In contrast to the benzimidazole class—exemplified by fenbendazole and albendazole, which bind to nematode β-tubulin and disrupt microtubule polymerization—diethylcarbamazine citrate does not provide the same broad gastrointestinal anthelmintic spectrum. Its veterinary use is centered on filarial nematodes, particularly Dirofilaria immitis prophylaxis in dogs and microfilaricidal protocols for canine and feline filarial infections. The precise molecular target has not been fully resolved; proposed mechanisms include interference with arachidonic acid metabolic pathways and alteration of host-derived adhesion molecule activity. Published data for this specific configuration is limited.

Compared with macrocyclic lactones such as ivermectin, which potentiate glutamate-gated chloride channels and are effective against a wider range of ectoparasites and gastrointestinal nematodes, diethylcarbamazine is narrower in spectrum and is not interchangeable with broad-spectrum dewormers. Praziquantel, which targets trematodes and cestodes, is mechanistically separate. The implication for formulation is that DEC citrate is frequently used as a targeted filaricide rather than as a standalone broad dewormer. In heartworm-endemic regions, historical daily administration of diethylcarbamazine citrate was largely replaced by monthly macrocyclic lactone preventives because of compliance and microfilaremic reaction risks; this clinical difference affected commercial positioning but not the synthetic route.

Veterinary-grade material differs from other products in regulatory status rather than chemical identity. In the EU, veterinary active substances are governed by EU Regulation (EU) 2019/6 and associated VICH guidelines; residual solvent testing according to VICH GL18 should be included. In the US, medicated feed applications fall under FDA 21 CFR 225 for Type B and Type C medicated feeds. These standards affect documentation, packaging, release testing, and audit trail expectations, not the molecular structure or primary pharmacopeial assay.

Batch-to-batch variance is controlled through particle-size classification, residual moisture, and impurity profile. Packaging should use double polyethylene liners in fiber drums with desiccant, and the product should be stored in tight, light-resistant containers at controlled room temperature. Reprocessing of opened partially used containers is not recommended; once exposed to ambient humidity above 60% RH, the material may require reconditioning and retesting before release.